ONAPGO (Apomorphine Hydrochloride) Patent Expiration, LOE Window & CMS Spending

ONAPGO (Apomorphine Hydrochloride) by Mdd Us Operations A Sub Of Supernus: FDA Orange Book LOE 2028-02-03, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $1,438 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMdd Us Operations A Sub Of Supernus
FDA Application & PathwayN214056 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2028-02-03
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,438 intro WAC)